Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 14251 - 14275 of 14533 in total

Xipamide

Experimental

Esaxerenone

Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension).
Investigational

Dipipanone

Experimental
Illicit

2,3,4,5,6-Pentafluorobenzyl Alcohol

Experimental

Balanol Analog 2

Experimental

N-[3-(aminomethyl)benzyl]acetamidine

Experimental

2-{4-[4-(4-Chloro-Phenoxy)-Benzenesulfonyl]-Tetrahydro-Pyran-4-Yl}-N-Hydroxy-Acetamide

Experimental

Diethyl 4-Methylbenzylphosphonate

Experimental

Iodobenzene

Experimental

1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea

Experimental

ES-936

Experimental

AL7182

Experimental

1-(N-Imidazolyl)-2-Hydroxy-2-(2,3-Dichlorophenyl)Octane

Experimental

(R)-Bicalutamide

Experimental

S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea

Experimental

4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole

Experimental

4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid

Experimental

PAS219

Experimental

(4-sulfamoyl-phenyl)-thiocarbamic acid O-(2-thiophen-3-yl-ethyl) ester

Experimental

FR239087

Experimental

4-Fluorophenethyl Alcohol

Experimental

Phenacetin

Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Withdrawn

1,3,5-trichlorobenzene

Experimental

4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid

Experimental

(P-Iodophenylacetylamino)Methylphosphinic Acid

Experimental
Displaying drugs 14251 - 14275 of 14533 in total